{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:36:41Z","timestamp":1787589401344,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006292","name":"Infectious Diseases Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunocompromised individuals are at heightened risk for severe influenza-related complications, yet vaccine responses may be attenuated due to underlying disease or immunosuppressive therapies. To inform clinical decision-making for the 2025\u20132026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened an expert panel to develop rapid evidence-based guideline on influenza vaccination for immunocompromised adults and children. The panel conducted a systematic review of literature published between August 2023 and July 2025, supplemented by analyses from the Vaccine Integrity Project. Only comparative effectiveness and harm data were included. Certainty of evidence and strength of recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.<\/jats:p>\n                  <jats:p>Direct evidence in immunocompromised populations was limited but demonstrated that influenza vaccination reduced influenza-associated hospitalization by 32%. Indirect evidence from older adult populations showed consistent reductions in hospitalization, intensive care unit admission, and all-cause mortality, supporting applicability to immunocompromised groups. No increased risk of Guillain\u2013Barr\u00e9 syndrome or serious adverse events was detected, and studies that evaluated autoimmune or immunocompromising disease exacerbation showed no significant safety concerns.<\/jats:p>\n                  <jats:p>Given moderate certainty of benefit and low likelihood of serious harm, IDSA strongly recommends that all immunocompromised individuals aged \u22656 months receive an age-appropriate 2025\u20132026 influenza vaccine. Vaccination should be individualized based on underlying conditions, timing of immunosuppressive therapy, and community influenza activity. High-dose or adjuvanted vaccines may offer enhanced immunogenicity. Household contacts should also be vaccinated to reduce transmission risk.<\/jats:p>\n                  <jats:p>Ongoing research is needed to define correlates of protection, optimize vaccine timing, improve real-world effectiveness data, and enhance strategies for patients with blunted immune responses.<\/jats:p>","DOI":"10.1093\/cid\/ciag116","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:45:43Z","timestamp":1772109943000},"page":"i117-i122","source":"Crossref","is-referenced-by-count":0,"title":["IDSA 2025 Guideline on the Use of Vaccines for the Prevention of Seasonal Influenza Infections in Immunocompromised Patients"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-5737","authenticated-orcid":false,"given":"Paul","family":"Goepfert","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham Division of Infectious Diseases, Department of Medicine, , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan J","family":"Katz","sequence":"additional","affiliation":[{"name":"Johns Hopkins University Division of Infectious Diseases, Department of Medicine, , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kaul","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School Division of Infectious Diseases, Department of Internal Medicine, , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3452-0666","authenticated-orcid":false,"given":"Tanvi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital and Harvard Medical School Division of Infectious Diseases, , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipleen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Infectious Diseases Society of America Clinical Affairs and Practice Guidelines, , Arlington, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Falck-Ytter","sequence":"additional","affiliation":[{"name":"Case Western Reserve University Faculty of Medicine, , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School Division of Infectious Diseases, , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026082412161466000_ciag116-B1","doi-asserted-by":"crossref","first-page":"1611.","DOI":"10.3390\/vaccines11101611","article-title":"Vaccination recommendations in solid organ transplant adult candidates and recipients","volume":"11","author":"Vigan\u00f2","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026082412161466000_ciag116-B2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/vaccines12121449","article-title":"Vaccination after haematopoietic stem cell transplant: a review of the literature and proposed vaccination protocol","volume":"12","author":"Silva-Pinto","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026082412161466000_ciag116-B3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082412161466000_ciag116-B4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2352-4642(22)00315-7","article-title":"Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer","volume":"7","author":"Furlong","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2026082412161466000_ciag116-B5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jiae508","article-title":"Vaccines for use in special populations: immunocompromised hosts","volume":"231","author":"Ison","year":"2025","journal-title":"J Infect Dis"},{"key":"2026082412161466000_ciag116-B6","doi-asserted-by":"crossref","first-page":"1040.e11","DOI":"10.1016\/j.cmi.2015.07.014","article-title":"Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe","volume":"21","author":"P\u00e9rez-Romero","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2026082412161466000_ciag116-B7","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira","year":"2021","journal-title":"Blood Adv"},{"key":"2026082412161466000_ciag116-B8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/21645515.2018.1445446","article-title":"Seasonal influenza vaccine in immunocompromised persons","volume":"14","author":"Bosaeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2026082412161466000_ciag116-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024\u201325 influenza season","volume":"73","author":"Grohskopf","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"2026082412161466000_ciag116-B10","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1016\/j.vaccine.2020.11.037","article-title":"Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity","volume":"39 Suppl 1","author":"Caldera","year":"2021","journal-title":"Vaccine"},{"key":"2026082412161466000_ciag116-B11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(09)70175-6","article-title":"Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses","volume":"9","author":"Kunisaki","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2026082412161466000_ciag116-B12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/cit725","article-title":"The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts","volume":"58","author":"Memoli","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026082412161466000_ciag116-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/cid\/ciad477","article-title":"Immunogenicity of high-dose versus MF59-adjuvanted versus standard influenza vaccine in solid organ transplant recipients: the Swiss\/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU trial)","volume":"78","author":"Mombelli","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026082412161466000_ciag116-B14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for Covid-19, RSV, and influenza vaccines for 2025\u20132026","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082412161466000_ciag116-B15","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026082412161466000_ciag116-B16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026082412161466000_ciag116-B17","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1093\/infdis\/jiaf185","article-title":"Vaccine effectiveness against influenza A(H1N1), A(H3N2), and B-associated hospitalizations, United States, 1 September 2023 to 31 May 2024","volume":"232","author":"Lewis","year":"2025","journal-title":"J Infect Dis"},{"key":"2026082412161466000_ciag116-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/vaccines13020189","article-title":"Safety and efficacy of influenza vaccination in kidney graft recipients in late period after kidney transplantation","volume":"13","author":"Zawiasa-Bryszewska","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026082412161466000_ciag116-B19","doi-asserted-by":"crossref","first-page":"e001370","DOI":"10.1136\/bmjgast-2024-001370","article-title":"Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study","volume":"11","author":"Nakafero","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"2026082412161466000_ciag116-B20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamaneurol.2023.2968","article-title":"Vaccines and the risk of hospitalization for multiple sclerosis flare-ups","volume":"80","author":"Grimaldi","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026082412161466000_ciag116-B21","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2214-109X(24)00473-X","article-title":"Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design","volume":"13","author":"Gharpure","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026082412161466000_ciag116-B22","doi-asserted-by":"crossref","first-page":"107364","DOI":"10.1016\/j.ijid.2024.107364","article-title":"Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023\/24 season: a population-based test-negative case-control study","volume":"151","author":"Mart\u00ednez-Baz","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026082412161466000_ciag116-B23","doi-asserted-by":"crossref","first-page":"2500102","DOI":"10.2807\/1560-7917.ES.2025.30.7.2500102","article-title":"Interim 2024\/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025","volume":"30","author":"Rose","year":"2025","journal-title":"Euro Surveill"},{"key":"2026082412161466000_ciag116-B24","doi-asserted-by":"crossref","first-page":"2500174","DOI":"10.2807\/1560-7917.ES.2025.30.12.2500174","article-title":"Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024\/25 influenza season up to 4 March 2025","volume":"30","author":"Emborg","year":"2025","journal-title":"Euro Surveill"},{"key":"2026082412161466000_ciag116-B25","doi-asserted-by":"crossref","first-page":"2400089","DOI":"10.2807\/1560-7917.ES.2024.29.8.2400089","article-title":"Interim 2023\/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024","volume":"29","author":"Maurel","year":"2024","journal-title":"Euro Surveill"},{"key":"2026082412161466000_ciag116-B26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.15585\/mmwr.mm7406a2","article-title":"Interim estimates of 2024\u20132025 seasonal influenza vaccine effectiveness\u2014four vaccine effectiveness networks, United States, October 2024-February 2025","volume":"74","author":"Frutos","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026082412161466000_ciag116-B27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.15585\/mmwr.mm7308a3","article-title":"Interim estimates of 2023\u201324 seasonal influenza vaccine effectiveness\u2014United States","volume":"73","author":"Frutos","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026082412161466000_ciag116-B28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eimc.2025.03.006","article-title":"Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023\/2024 season in a Spanish health department","volume":"43","author":"Silva-Afonso","year":"2025","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2026082412161466000_ciag116-B29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciae597","article-title":"Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023\u20132024 season, United States","volume":"81","author":"Tenforde","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026082412161466000_ciag116-B30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/vaccines13030309","article-title":"The effectiveness of four quadrivalent, inactivated influenza vaccines administered alone or in combination with pneumococcal and\/or SARS-CoV-2 vaccines: a population-wide cohort study","volume":"13","author":"Acuti Martellucci","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026082412161466000_ciag116-B31","doi-asserted-by":"crossref","first-page":"127069","DOI":"10.1016\/j.vaccine.2025.127069","article-title":"Safety monitoring of health outcomes following influenza vaccination during the 2023\u20132024 season among U.S. Medicare beneficiaries aged 65 years and older","volume":"53","author":"Lloyd","year":"2025","journal-title":"Vaccine"},{"key":"2026082412161466000_ciag116-B32","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.vaccine.2024.04.051","article-title":"Assessment of potential adverse events following the 2022\u20132023 seasonal influenza vaccines among U.S. adults aged 65 years and older","volume":"42","author":"Shi","year":"2024","journal-title":"Vaccine"},{"key":"2026082412161466000_ciag116-B33","doi-asserted-by":"crossref","first-page":"e16172","DOI":"10.1111\/ene.16172","article-title":"Risk of stroke within 3, 7, 14, 21 and 30 days after influenza vaccination in Alberta, Canada: a population-based study","volume":"31","author":"Tanaka","year":"2024","journal-title":"Eur J Neurol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag116\/67174420\/ciag116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i117\/67174420\/ciag116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i117\/67174420\/ciag116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:16:24Z","timestamp":1787588184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/Supplement_3\/i117\/8502103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":33,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2026,2,28]]},"published-print":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag116","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2026,2,28]]}}}